Elevance Health, Inc. (ELV) · Sep 10, 2026 · Guidance

Elevance reaffirms 2026 EPS outlook, offering no new upside after Q2 raise

Guidance reaffirmed — Adjusted EPS at least $27.00, unchanged from the Q2 guidance raise

Elevance kept its 2026 earnings floor unchanged at $27 adjusted EPS. The filing confirms stability, not another upgrade.

The filing confirms the existing outlook rather than changing it. Elevance says officers will reaffirm full-year 2026 shareholders’ earnings of at least $20.10 per diluted share, including approximately $6.90 per share of net unfavorable items.

Metric2026 outlookMarket context
Reported shareholders’ earningsAt least $20.10 per diluted shareUnchanged from prior guidance
Net unfavorable itemsApproximately $6.90 per diluted shareIncluded in reported outlook
Adjusted shareholders’ earningsAt least $27.00 per diluted shareSame floor established after Q2

The adjusted-earnings floor remains the key number, and it was already known. The company continues to expect adjusted shareholders’ earnings of at least $27.00 per diluted share. That $27.00 floor was raised with the second-quarter results, so today’s filing preserves the improved outlook but does not add another increase.

Net read: stable, not incremental. The filing reduces concern that the post-Q2 outlook had deteriorated, but it does not constitute a fresh beat or upgrade versus the standing expectation. With no new financial data, new cost assumptions, or higher target, the appropriate scorecard is guidance reaffirmed and the information is effectively priced in.

What to watch next

Q3 earnings report, late October

Original filing on SEC EDGAR

More Elevance Health, Inc. news

Elevance reaffirms 2026 EPS outlook, offering no new upside after Q2 raise | ELV Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.